Objective:To establish an HPLC method for the determination of the content of magnolol and honokiol in Cortex mag-noliae Officinalis formula granules and compare the content of the formula granules from different manufacturers. Methods:An HPLC was used to determine the content of magnolol and honokiol in Cortex magnoliae Officinalis formula granules. The analysis was carried out on a Hypersil C18 (250 mm × 4. 6 mm, 5 μm) chromatographic column. Acetonitrile-water was used as the mobile phase with gra-dient elution and the flow rate was 1. 0 ml·min-1 . The detection wavelength was set at 294 nm, the sample size was 20 μl and the column temperature was 25℃. Results:The linear range was 0. 873-26. 190μg·ml-1(r=0. 999 5) for magnolol, the average recov-ery was 99. 24% with RSD of 2. 00%(n=6) and that was 0. 732-21. 980μg·ml-1(r=0. 999 0) for honokiol,and the average recov-ery was 99. 89% with RSD of 1. 33%(n=6). The difference in the content of magnolol and honokiol in Cortex magnoliae Officinalis formula granules from different manufacturers was notable. Conclusion: The method is simple, repeatable and feasible, and can be used for the quality control of magnolol and honokiol in Cortex magnoliae Officinalis formula granules. The content difference in magno-lol and honokiol in Cortex magnoliae Officinalis formula granules from different manufacturers suggests that it is necessary to standardize the planting and selecting of Chinese medicine, and develop scientific and unified production technology and quality standard for the formula granules.

OBJECTIVE To establish the drug use evaluation(DUE) standard of ticagrelor, and to provide a reference for the rational clinical application of ticagrelor. METHODS Based on the ticagrelor drug label, related guidelines and literature, combined with clinical expert consultation results, DUE standard from three levels (indications, medications and medication results) was established. A retrospective survey was conducted to evaluate the inpatients using ticagrelor from January 2021 to December 2021 in the Second Affiliated Hospital of Fujian University of Traditional Chinese Medicine. RESULTS The DUE of ticagrelor was divided into three levels, including 3 first-level indexes, 14 second-level indexes and 60 third-level indexes. A total of 263 cases of using ticagrelor were included, of which the irrational rate was 72.62%. The irrational cases were mainly off-label use (60.08%), inappropriate drug conversion(14.83%) and unreasonable usage and dosage(5.70%), etc. CONCLUSION The established DUE standard of ticagrelor is scientific, practical and feasible, which can provide reference for clinical rational drug use and prescription evaluation.